LJLukas T. Jeker

Lukas T. Jeker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lukas T. Jeker has a total of 422 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia model

    by Romina Marone, Rosalba Lepore, Kiriaki Paschoudi, Jessica Zuin, Alessandro Sinopoli, Anna Camus, Thomas Burgold, Ewelina Bartoszek, Diego Calabrese, Mylène Toranelli, et al.

    SUMMARY: Clinical evidence demonstrates that ex vivo gene therapy and genome engineering of hematopoietic stem and progenitor cells (HSPCs) could represent one-time cures. However, while genome editing itself has become increasingly efficient and precise, the toxic conditioning required for hematopoietic stem cell transplantation remains a major barrier to broad clinical implementation of these otherwise curative therapies. In particular, the use of busulfan for myeloablative conditioning constitutes a major safety concern. While preclinical studies established CD117 as a promising target for antigen-specific therapy, clinical translation faced setbacks balancing efficacy and safety. To overcome current limitations, we generated a new CD117-blocking monoclonal antibody (CIM058) and demonstrate its potency to block wild-type HSPCs. To enable long-term blockade of host HSPCs even after transplantation, we used prime editing to engineer CIM058-resistant human CD34 + HSPCs. When combined, CIM058 and the epitope engineered CD34 + HSPCs ameliorated disease phenotype in a β-thalassemia model. Our results suggest that this approach may overcome the reliance on busulfan or other myeloablative conditioning regimens with their associated morbidities, and by enabling toxin-free conditioning and in vivo selection of edited cells, may facilitate clinical implementation of these highly valuable genetic therapies.

  • Open Access

    KLRG1 identifies circulating cytotoxic CD4 T cells with selective anti-tumor function in human cancer

    by Mara Cenerenti, Josep Garnica, Margaux Saillard, Paul Gueguen, Benita Wolf, Florent Lemaitre, Romina Marone, Yen-Cheng Liu, Anthony Cornu, Alexandre Dumez, et al.

    Given the critical role of CD4 T cells in anti-tumor immunity, strategies to harness these cells for cancer immunotherapy are gaining increasing interest. Historically overshadowed by CD8 T cells, cytotoxic CD4 T cells can directly kill MHC class II-expressing tumor cells. However, the defining molecular signature and the mechanisms underlying their cytolytic activity remain poorly understood, particularly in cancer patients. Here, using ex vivo single-cell transcriptomic and spatial analyses of CD4 T cells from paired blood and tumor samples of melanoma patients, we identified Killer Cell Lectin-Like Receptor G1 (KLRG1) as a defining surface marker of cytotoxic CD4 T cells. The CD4 + KLRG1 + T cell subset was notably enriched among circulating cells compared with tumor-infiltrating populations, which were instead enriched in T follicular helper (Tfh) states. Functionally, KLRG1 + CD4 T cells expressed elevated levels of cytotoxic genes and exhibited superior tumor-killing capacity compared with their KLRG1 - counterparts. We demonstrated that their cytotoxicity is granulysin-dependent, as confirmed by CRISPR/Cas9-mediated gene deletion. Mechanistically, CD4 T cells spared MHC class II + cells lacking the KLRG1 ligands CD324 and CD325, such as professional antigen-presenting cells (APCs), indicating that cytotoxicity was selectively directed towards tumor cells while preserving immune cells. Finally, by investigating how the tumor microenvironment may impair CD4 T cell cytotoxicity, we showed that tumor-derived factors, including interleukin-6 (IL-6), are key drivers promoting the transition of cytotoxic CD4 T cells toward a Tfh phenotype. In summary, our findings define KLRG1 as a defining cell surface marker of cytotoxic CD4 T cells in cancer patients, as well as a key regulator that protects MHC class II + APCs. Moreover, targeting the IL-6 signalling pathway may enhance CD4 T cell anti-tumor cytotoxicity, offering new avenues for cancer immunotherapy.


  • Open Access

    Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer

    by Maryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, Ziyang Su, Anthony Cornu, Tania Wyss, Burak Kizil, Robert Pick, Katayoun Falamaki, Pratyaksha Wirapati, et al.

    Innate lymphoid cells type 2 (ILC2s) are key regulators of tissue homeostasis and inflammation. In cancer, ILC2s can exhibit pro-tumoral functions by increasing the myeloid derived suppressor cells (MDSC)/T-cell ratio. Nevertheless, the upstream ILC2 triggers remain poorly defined. Here, we identify nerve growth factor (NGF) as the driver of ILC2 pro-tumoral functions in patients with bladder cancer. We show that ILC2s express the NGF receptor TrkA and respond to NGF by secreting type-2 cytokines. In the tumor microenvironment, NGF-producing mast cells accumulate and activate ILC2s to induce regulatory T cells (Tregs), ultimately fostering tumor growth. In patients, NGF levels inversely correlate with survival in ILC2-rich tumors, underscoring the clinical significance of this axis. In vivo administration of a selective TrkA inhibitor improves survival in orthotopic tumor-bearing female mice and sensitizes them to immune checkpoint blockade (ICB). Overall, we identify NGF as an ILC2 activator that shapes pro-tumoral ILC2 functions. The blockade of TrkA + ILC2s might represent a targetable strategy to improve survival, particularly in ICB-resistant patients.


  • Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies

    by Romina Marone, Erblin Asllanaj, Giuseppina Capoferri, Torsten Schwede, Lukas T. Jeker, Rosalba Lepore

    Monoclonal antibodies have transformed the therapeutic landscape across oncology, immunology, and infectious diseases by enabling high-affinity, antigen-specific targeting to neutralize soluble molecules, block cellular interactions, or deplete cells. Although high specificity is critical for safety, it may confer an inherent susceptibility to even minor variations in the target epitope. Here, we investigated the impact of natural single-nucleotide variants on antigen recognition by therapeutic monoclonal antibodies, both approved and in clinical development. For almost every antibody analyzed, we identified protein variants in or near the antibody-antigen interface, a subset of which were predicted to disrupt antigen recognition. Experimental studies corroborated the impact of select variants for four different antigens, revealing complete loss of antibody binding in some cases. For example, a human breast cancer cell line overexpressing human epidermal growth factor receptor 2 (HER-2), but engineered to carry the HER-2 P594H variant, was completely resistant to killing even by highly potent clinical antibody-drug conjugates. These findings suggest that natural variants can confer primary resistance to antibody-based therapies, with critical implications for treatment outcomes, patient management, and safety, particularly in the context of potent modalities such as antibody-drug conjugates. Individual resistance-associated variants, although globally rare, are enriched in specific populations, underscoring the importance of accounting for genetic diversity in both drug development and clinical decision-making.


  • Open Access

    Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma

    by Michael T. Sandholzer, Clara Serger, Alessia G. Liner, Sarp Uzun, David König, Helen Thut, Reto Ritschard, Jonas D. Fürst, Andreas Zingg, Natalia Rodrigues Mantuano, et al.

    Adoptive cell therapy (ACT) with expanded autologous tumor-infiltrating lymphocytes (TILs) can induce durable responses in metastatic melanoma, yet many patients relapse. We profiled tumor-reactive T cell dynamics during TIL therapy using single-cell RNA and TCR sequencing from seven patients to elucidate underlying reasons. We found that tumor-reactive T cells preferentially expanded early during ex vivo TIL culture, transitioning from exhausted to reinvigorated effector states. Particularly, CD8 + exhausted T cells (Tex) and CD4 + follicular helper T cell (Tfh), but not CD4 + Tex, were efficiently reinvigorated. Further, we resolved the heterogeneity of tumor-reactive CD8 + and CD4 + subsets, defining unique signatures for their identification during TIL expansion. In addition, non-responders (NRs) exhibit increased levels of Type 17 T cells in TIL products, suggesting a potential association with resistance to therapy. After transfer, tumor-reactive clones rapidly extravasated and established a stem-like reservoir. However, in NRs, CD4 + regulatory T cells (Tregs) expanded de novo and tumor-reactive CD8 + T cells reacquired exhaustion markers, limiting their functionality. By contrast, responders (Rs) retained a pool of less differentiated, stem-like cells. Collectively, these data provide a comprehensive analysis of T cell fates during TIL-ACT providing the basis for new approaches to enhance therapeutic strategies.


  • Open Access

    Tmem127-mediated immune receptor degradation regulates T cell homeostasis through the common gamma chain

    by Marko Hasiuk, Arlinda Negraschus, Denis Seyres, Romina Marone, Gytis Jankevicius, Lena Siewert, Christoph Schultheiss, Aida Muñoz Blázquez, Mascha Binder, Anne-Katrin Proebstel, et al.

    Maintenance of T cell population size, which is important for immune homeostasis, is controlled by interleukin-7 (IL-7) and low-affinity TCR/MHC interactions that provide limited survival cues. Using arrayed CRISPR screening of miR-17∼92 targets, Bio-ID proximity labeling and proteomics we identified Tmem127 as an essential regulator of the T cell surface proteome. We validated interaction with the common gamma chain (IL-2Rγ) in a multi-protein complex. Tmem127 reduces IL-7 receptor surface expression to restrict homeostatic proliferation, thereby controlling naïve and central memory T cell population sizes. Tmem127 germline knockout (KO) mice display splenomegaly, accelerated experimental autoimmune encephalomyelitis and Tmem127-deficient bone marrow displays a competitive advantage over wildtype cells. Thus, we identified Tmem127 as an important regulator of the common gamma chain and immune homeostasis.

  • Open Access

    Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific Immunotherapy

    by Romina Marone, Erblin Asllanaj, Giuseppina Capoferri, Torsten Schwede, Lukas T. Jeker, Rosalba Lepore

    Monoclonal antibodies have transformed the therapeutic landscape across oncology, immunology, and infectious diseases by enabling high-affinity, antigen-specific targeting, e.g. to neutralize soluble molecules, block cellular interactions or deplete cells. While high specificity is critical for safety, it may confer an inherent susceptibility to even minor variations within the target epitope. Here, we present the first systematic study investigating the impact of natural single nucleotide variants on antigen recognition by therapeutic monoclonal antibodies, both approved and in clinical development. For every antibody analysed, we identified genetic variants within or near the antibody-antigen interface, a subset of which are predicted to disrupt antigen recognition. Experimental studies corroborated the impact of select variants for four different antigens, revealing complete loss of antibody binding in some cases. As a consequence, a human breast cancer cell line overexpressing ErbB2 but engineered to carry the ErbB2 P594H variant, was completely resistant to killing even by highly potent clinical antibody-drug conjugates (ADCs). These findings suggest that natural variants can confer primary resistance to antibody-based therapies, with critical implications for treatment outcomes, patient management and safety, particularly in the context of potent modalities such as ADCs. Notably, individual resistance-associated variants, while globally rare, are enriched in specific populations, underscoring the importance of accounting for genetic diversity in both drug development and clinical decision-making. One sentence summary: Naturally occurring genetic variants in human therapeutic target antigens can affect binding by almost any therapeutic antibody.


  • Open Access

    Identification of DOK2 and PTPN11 as novel interactors of T cell specific adapter protein TSAd

    by Hanna Chan, Pawel Borowicz, Brian C Gilmour, Maria Stensland, Ivan Garcia-Loza, Santosh Phuyal, Romina Marone, Lukas T. Jeker, Tuula A Nyman, Anne Spurkland

    T cells play a crucial role in the adaptive immune system and depend on tightly regulated intracellular signalling pathways to respond in an appropriate manner. Adapter proteins have flexible and dynamic features, which allow them to regulate T cell signal transduction pathways. As adapter proteins are enzymatically inert and may play multiple roles in parallel, it has been a challenge to fully characterise their functions individually. One such protein in T cells, is T cell specific adapter protein (TSAd), which is upregulated following T cell receptor (TCR) stimulation and is believed to mediate Src family tyrosine kinase signalling. However, the functional role remains elusive, possibly due to limited insight into interactors that potentially bind TSAd. The only structurally well-defined feature within TSAd, is the Src homology 2 (SH2) domain. This conserved domain displays prototypic binding of phosphorylated tyrosines, which suggests that the adapter molecule is implicated in phosphotyrosine signalling pathways. Here, we used an unbiased approach to identify ligands of the TSAd SH2 domain, by using affinity-purification mass spectrometry (AP-MS). Several novel ligands, many of which are known to be implicated in negative regulation of T cell intracellular signalling, were identified. More specifically, we showed that TSAd binds DOK2 and PTPN11 and determined the tyrosines responsible for the TSAd SH2 domain-dependent interaction. Ablation of TSAd and DOK2 by CRISPR/Cas9 in Jurkat T cells resulted in altered tyrosine phosphorylation. Taken together, these findings provide new insight into the possible function of TSAd as a negative signalling node in T cells.

  • Open Access

    Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes

    by David König, Michael T. Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth A. Kappos, Dirk J. Schaefer, Christoph Kettelhack, et al.

    Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.

  • Open Access

    Supplementary Figure 6 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes

    by David König, Michael T. Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth A. Kappos, Dirk J. Schaefer, Christoph Kettelhack, et al.

    Supplementary Figure 6. Expression analysis of selected exhaustion markers on different T cells on T cells in the tumor lesion used for TIL expansion.